Apellis hits full-year profitability as Syfovre sales top half-billion dollars
Apellis Pharmaceuticals (NASDAQ:APLS) reported a milestone fiscal year 2025, delivering total net product revenues of $689 million and achieving its first year of net profitability.




-12-640x360.png&w=3840&q=75)





